Nutraveris

Category 'NEWS'

Tuesday, March 19, 2019
Category : NEWS, TRAINING | Author : experts | Comment : No Comments
Tags:

Sorry, this entry is only available in French.

NOL, Nutraveris Online, the most efficient data solution to create, keep up-to-date and launch your products in the 28 EU member states, used for 10years by more than 500 industry leaders informs you:

 

Red yeast rice has been suspected to induce some toxicological side effects. The aim of this systematic review and meta-analysis was to examine the available scientific evidences on the safety of red yeast rice supplementations. Data were pooled from 53 randomized and controlled trial, for a total of 8535 subjects (5537 supplemented with red yeast rice and 4303 controls).

Red yeast rice

Results showed that red yeast rice was not associated with increased risk of musculoskeletal disorders (OR = 0.94, 95% CI: 0.53-1.65). In addition, reduced risk of non-skeletal musculoskeletal adverse events (OR = 0.59, 95% CI: 0.50-0.69) and serious adverse events (OR = 0.54, 95% CI: 0.46-0.64) have been measured with red yeast rice in comparison to control. Furthermore, increasing the doses of monacolin K was negatively associated with increasing risk of non-skeletal musculoskeletal adverse events.

 

In conclusion, this large meta-analysis demonstrate that the use of red yeast rice as hypocholesterolemic supplement is not associated with safety concern.

 

 

Fogacci F, Banach M, Mikhailidis DP, Bruckert E, Toth PP, Watts GF, Reiner Ž, Mancini J, Rizzo M, Mitchenko O, Pella D, Fras Z, Sahebkar A, Vrablik M, Cicero AFG; Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group the International Lipid Expert Panel (ILEP). SAFETY OF RED YEAST RICE SUPPLEMENTATION: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. Pharmacol Res. 2019 Mar 4. pii: S1043-6618(19)30317-2.

 

This information has been sourced by NOL, a collaborative and complete tool which contains all Regulatory, Scientific and Marketing data

  • It solves all regulatory issues since it contains the required information on all ingredients authorized in the 28 European member states…on regulatory status, health claims, authority opinions
  • It protects your investments since it is updated in real time with reliable quality information analyzed and reviewed by our experts, available hotline.
  • It enables you to be the most responsive with monthly reports and live alerts and a personal use of the information with a report editing tool and customizable bookmarks.

With NOL let’s : 

  • Formulate new innovative products
  • Check if your already existing formulas are still compliant with the in force regulations
  • Adapt your existing formulas to the requirements of other European countries where you are willing to export them
  • Do scientific & regulatory & marketing monitoring which enable to anticipate the withdrawal of products, the safety issues, new interesting scientific studies, the arrival of new players on the market…

 

More information on www.nutraveris.com

Contact our Scientific & Regulatory experts at NUTRAVERIS

contact@nutraveris.com, +33 2 96 76 54 87

Thursday, March 14, 2019
Category : NEWS, INGREDIENTS, CLINICAL EVIDENCE | Author : experts | Comment : No Comments
Tags:

NOL, Nutraveris Online, the most efficient data solution to create, keep up-to-date and launch your products in the 28 EU member states, used for 10years by more than 500 industry leaders informs you:

 

This randomized, double-blind, placebo-controlled trial evaluated the effects of melatonin administration on metabolic status in 60 diabetic patients with coronary heart disease (CHD).

Subjects were allocated into two groups to receive either 10 mg melatonin (2 melatonin capsules, 5 mg each) (n = 30) or placebo (n = 30) once a day for 12 weeks.

 

cardio-metabolic risk

 

Taking melatonin, compared with the placebo, significantly reduced fasting plasma glucose (p = 0.03), serum insulin concentrations (p = 0.008), homeostasis model of assessment-estimated insulin resistance (p = 0.04), total-/HDL-cholesterol ratio (p = 0.02) and systolic (p = 0.01) and diastolic blood pressure (p = 0.04). Melatonin treatment also significantly increased quantitative insulin sensitivity check index (p = 0.01) and serum HDL-cholesterol (p = 0.04).

In addition, compared with the placebo, melatonin supplementation resulted in significant increases in plasma glutathione (p = 0.02) and nitric oxide (p = 0.03), and significant decreases in malondialdehyde (p = 0.007), protein carbonyl (p < 0.001) and serum high sensitivity C-reactive protein levels (p = 0.001).

Overall, melatonin intake for 12 weeks to diabetic patients with CHD had beneficial effects on biomarkers of oxidative stress and cardio-metabolic risk.

 

Raygan F, Ostadmohammadi V, Bahmani F, Reiter RJ, Asemi Z. Melatonin administration lowers biomarkers of oxidative stress and cardio-metabolic risk in type 2 diabetic patients with coronary heart disease: A randomized, double-blind, placebo-controlled trial. Clin Nutr. 2019 Feb;38(1):191-196.

 

This information has been sourced by NOL, a collaborative and complete tool which contains all Regulatory, Scientific and Marketing data

  • It solves all regulatory issues since it contains the required information on all ingredients authorized in the 28 European member states…on regulatory status, health claims, authority opinions
  • It protects your investments since it is updated in real time with reliable quality information analyzed and reviewed by our experts, available hotline.
  • It enables you to be the most responsive with monthly reports and live alerts and a personal use of the information with a report editing tool and customizable bookmarks.

With NOL let’s : 

  • Formulate new innovative products
  • Check if your already existing formulas are still compliant with the in force regulations
  • Adapt your existing formulas to the requirements of other European countries where you are willing to export them
  • Do scientific & regulatory & marketing monitoring which enable to anticipate the withdrawal of products, the safety issues, new interesting scientific studies, the arrival of new players on the market…

 

More information on www.nutraveris.com

Contact our Scientific & Regulatory experts at NUTRAVERIS

contact@nutraveris.com, +33 2 96 76 54 87

Tuesday, March 12, 2019
Category : NEWS, REGULATORY | Author : experts | Comment : No Comments
Tags:

NOL, Nutraveris Online, the most efficient data solution to create, keep up-to-date and launch your products in the 28 EU member states, used for 10years by more than 500 industry leaders informs you:

 

The Regulation (EU) 2019/343 of 28 February 2019 providing derogations from Article 1(3) of Regulation (EC) No 1924/2006 on nutrition and health claims made on food for the use of certain generic descriptors has been published in the Official Journal of the EU.

Official Journal EU

 

The annex of this new Regulation establishes the list of generic descriptors exempted from the application of Article 1(3) of Regulation (EC) 1924/2006 under the conditions laid down in that Annex (class of food, Member States where the exemption is valid).

Examples:

« Biscotto salute » in Italy

« Tonic» for specified beverages in all Member States

« Cough drops », « Rebuçados para a tosse »,… for some sweets (variations depending on the Member States).

 

This information has been sourced by NOL, a collaborative and complete tool which contains all Regulatory, Scientific and Marketing data

  • It solves all regulatory issues since it contains the required information on all ingredients authorized in the 28 European member states…on regulatory status, health claims, authority opinions
  • It protects your investments since it is updated in real time with reliable quality information analyzed and reviewed by our experts, available hotline.
  • It enables you to be the most responsive with monthly reports and live alerts and a personal use of the information with a report editing tool and customizable bookmarks.

With NOL let’s : 

  • Formulate new innovative products
  • Check if your already existing formulas are still compliant with the in force regulations
  • Adapt your existing formulas to the requirements of other European countries where you are willing to export them
  • Do scientific & regulatory & marketing monitoring which enable to anticipate the withdrawal of products, the safety issues, new interesting scientific studies, the arrival of new players on the market…

 

More information on www.nutraveris.com

Contact our Scientific & Regulatory experts at NUTRAVERIS

contact@nutraveris.com, +33 2 96 76 54 87

 

Friday, March 8, 2019
Category : NEWS, TRAINING | Author : experts | Comment : No Comments
Tags:

Sorry, this entry is only available in French.